Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

Authors :: Monica Bocchia
Angela Michielutti
Luigi Gugliotta
Donatella Raspadori
Maurizio Castelli
Renato Fanin
Paolo Avanzini
Domenico Russo
Alessandro Bonini
Giancarla Pricolo
Alfonso Zaccaria
M Malagola
Eliana Zuffa
Nicoletta Testoni
Francesco Lauria
Antonio De Vivo
Patrizio Mazza
Pier Paolo Piccaluga
Michele Baccarani
Emanuela Ottaviani
Anna Candoni
Mauro Fiacchini
Daniela Damiani
Giuseppe Visani
Michela Rondoni
Giovanni Martinelli
Russo D
Malagola M
Vivo A
Fiacchini M
Martinelli G
Piccaluga PP
Damiani D
Candoni A
Michielutti A
Castelli M
Testoni N
Ottaviani E
Rondoni M
Pricolo G
Mazza P
Zuffa E
Zaccaria A
Raspadori D
Bocchia M
Lauria F
Bonini A
Avanzini P
Gugliotta L
Visani G
Fanin R
Baccarani M
Publication Year :: 2005
Abstract: Summary Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated induction regimen for the treatment of acute myeloid leukaemia (AML). This phase III trial compared the efficacy and toxicity of FLAI versus idarubicin plus Ara-C and etoposide (ICE) in 112 newly diagnosed AML patients

Tools